Andy Acker
Portfolio Manager, Janus Henderson Investors. On 1 show, 1 appearance. The Shows tab opens the full record on each.
investoranalystjanushenderson.com/en-us/advisor/bio/andy-acker ↗
Andy Acker oversees Janus Henderson's healthcare and biotechnology strategies, including the Global Life Sciences Fund. He joined Janus in 1999 as a biotech analyst after earlier roles at Boston Consulting Group and Morgan Stanley Venture Partners.
1shows
1appearances
17statements
11resolved
10supported
0contradicted
91%fully supported
1said about them ↓ Everything Andy Acker said on any show that made the record, most notable first. Each card names its show and opens the statement there.
Acker: Wall Street drug launch estimates are wrong 90% of the time
“And what we've found again in more than 23 years of investing in health care is that the consensus estimates from Wall Street Are wrong about 90% of the time.”
Acker: Muscular dystrophy gene therapy could potentially launch by mid-2023
“There's been no disease-modifying therapy, and now we have a gene therapy that could be launching potentially by the middle of 2023.”
Acker: A bad management team can destroy a great drug molecule
“Probably the biggest mistake that I've made in my career is underappreciating how important a good management team is, because if you have a great molecule and it meets a bad management team, you can destroy a tremendous amount of value just by making bad deci…”
Acker: Biotech stocks fell 64% absolute and 75% relative in 2021-2022
“Between February of 2021 and June of 2022, we had one of the worst bear markets in biotech sector in history. So on an absolute basis, these stocks declined 64% and relative to the health care sector, they traded down about 75%.”
Acker: Over 200 biotech companies traded below cash after the 2022 crash
“Now, after that, you get to a point where actually 200 different companies were trading below the levels of cash on their balance sheet. That's highly unusual. We've never seen that before, even going back to The global financial crisis and the bear market, th…”
Acker: Small and mid-cap biotechs develop over 60% of new medicines
“Over 60% of the new medicines that reach the market today were developed by small and mid cap biotech companies.”
Acker: Janus Henderson invested in BioNTech in 2017 at $2B valuation
“BioNTech, which is the company that made the first MRNA vaccine along with Pfizer, we invest in that company when it was still a private company back in 2017 when most people had never heard of MRNA... Back then the company had a two billion market cap in 2021…”
Acker: Buy hated biotech companies after trial setbacks if the drug works
“So it's really buying when a company is the most controversial, the most hated, but where you have high conviction that a product really works.”
Acker: Healthcare investors can have a bigger impact than practicing physicians
“I also felt that I could have a bigger impact as an investor than I could as a practicing physician. And then what's been really gratifying is that's turned out to be true.”
Acker: Human Genome Sequencing Takes Hours for Hundreds of Dollars
“Now we can sequence a human genome literally in hours, and we can do it for hundreds of dollars.”
Acker: US Drug Approvals Rose Over 100% Across Five Years
“In the last five years, there have been 256 new medicines approved in the United States, and that's up over a hundred percent from where we were just 10 years ago.”
Acker: 90% of drugs entering clinical trials never reach the market
“If you look at the industry over the last multiple decades, 90% of the products that begin human clinical testing never make it all the way to market.”
Acker: The industry average success rate for Phase 3 trials is 50%
“And if you think about the industry statistics for a phase three study, the average success rate of the industry is about 50%.”
Acker: Physician prescriptions determine 80% of healthcare spending
“So the physicians write the prescriptions that affect 80% of healthcare spending.”
Acker: Biotech experienced eleven bear markets of over 20% since 2006
“Back when the SMP select biotech index and the XBI, which is an ETF that tracks that broad biotech index that was created back in 2006. So about 16 years ago, since that time before the recent bear market, and we'll get to that, but there were 11 effectively b…”
Acker: About a third of patients don't fill prescriptions due to co-pays
“Today, about a third of patients don't fill their prescriptions because of the co-pays that they can't afford”
The other half of the tape: Andy Acker's own voice is left out of every number here. Other people bring the name up 1 time in 1 episode across the shows. every mention, with the transcript →
Who brings them up most Ted Seides 1
Every mention by year
tap a year for its mentions
Capital Allocators 1
2023 1 mention in 1 episode
One line per show, most statements first. The link opens Andy's full record on that show: the calibration, argument clarity, speaking style and every statement made there.
| Show | Role there | Eps | Statements | Record | |
|---|---|---|---|---|---|
| CAPITAL ALLOCATORSLEDGER | Portfolio Manager, Janus Henderson Investors | 1 | 17 | 91% 10/11 | full record on Capital Allocators → |